Thompson bemoans policy on drug costs and safety

Share this article:
Tommy Thompson has criticized his lack of control over prescription
drug costs and federal drug safety policy while serving as secretary of Health and Human Services.
Freed from the binds of administration policy following his recent
resignation, Thompson told reporters at a press conference he
wished Congress had given him the power to negotiate with drug manufacturers to secure lower prices for Medicare beneficiaries.
The White House and Republicans in Congress have long been staunch opponents of giving government that power because it would likely lead to price controls, cutting revenues needed for pharmaceutical research.
Thompson also said he favored the creation of an independent office to analyze the safety of prescription drug products after they are
approved for sale to the public.
Critics of the FDA have long calledfor such an office.
After initial opposition to the idea, members of the Bush administration and managers at the FDA have been noncommittal in recent weeks, a New York Times report said.
Medicare and Medicaid administrator Mark McClellan, brother to
White House press secretary Scott McClellan, was widely expected
to be Bush's choice to succeed Thompson.
His resignation made Thompson the eighth member of President
Bush's cabinet to give up their postsince the Nov. 2 election.
Thompson said he would remain in office until Feb. 4 or until the Senate confirmed a successor.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...